Oxford-AstraZeneca's Phase III COVID-19 vaccine data could be available by December
University of Oxford says it hopes to present interim data of its COVID-19 vaccine candidate AZD1222 to regulators by as early as next month and it could be one of first vaccines submitted for regulatory approval, alongside Pfizer and BioNTech’s vaccine candidate BNT162b2.
Source:
Biospace Inc.
SPS commentary:
If approved, the Oxford-AstraZeneca vaccine could possibly roll out by late December or early 2021. AstraZeneca has said it plans to produce two billion doses of AZD1222 pending regulatory approval. Approximately 400 million doses are slated for the U.S. and UK.
Reuters reports that the timetable for delivery of this vaccine candidate has slipped, with UK only receiving 4 million doses this year. The UK Vaccine Taskforce Chair said that the vaccine was being made in bulk first, known as “drug substance”, but could not yet be put into vials until more was known on the timing of late-stage trial data.